| Literature DB >> 15907907 |
Irene H Heijink1, Antoon J M Van Oosterhout.
Abstract
The type 2 T-helper (Th2) lymphocyte can be regarded as an important target cell for the treatment of allergic asthma as it plays a crucial role in the initiation, progression and persistence of disease. Several strategies to target Th2 cells can be envisioned. Drugs that prevent Th2-cells from migrating into the lung tissue, such as antibodies to the chemokine receptor CCR4 and inhibitors of the adhesion molecule VLA-4, are promising for the treatment of asthma. To inhibit Th2-cell activation, novel asthma drugs that act on Th2-selective transciption factors such as GATA3 are being developed. Although initial strategies aimed to block the action of Th2-derived cytokines, the generation of counter-regulatory Th1 lymphocytes and regulatory T cells is currently being explored.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15907907 DOI： 10.1016/j.coph.2005.04.002
Source DB: PubMed Journal: Curr Opin Pharmacol ISSN： 1471-4892 Impact factor: 5.547